ProtonRadiotherapy for Pediatric Brain Tumors Requiring Partial BrainIrradiation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Some patients with brain tumors receive standard radiation to help prevent tumor growth. Although standard radiation kills tumor cells, it can also damage normal tissue in the process and lead to more side effects. This research study is looking at a different form of radiation called protonradiotherapy which helps spare normal tissues while delivering radiation to the tumor or tumor bed. Proton techniques irradiate 2-3 times less normal tissue then standard radiation. This therapy has been used in treatment of other cancers and information from those other research studies suggests that this therapy may help better target brain tumors then standard radiation.
- Participants will receive proton radiotherapy at the Francis H. Burr Proton Therapy Center which is located at the Massachusetts General Hospital. They will receive the proton radiotherapy 5 days per week. The number of weeks the participant will be receiving proton radiotherapy depends upon the tumor type and location and how well they are tolerating the treatment. Participant's will have a physical exam weekly during proton radiotherapy treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Year to 25 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Biopsy proven low grade glioma or astrocytoma, ependymoma, craniopharyngioma, meningioma, neurocytoma, medulloblastoma or gangliogliomas or other rare tumor requiring tumor bed or tumor irradiation. Patients with a presumed diagnosis of optic glioma or gliomas based on imaging and clinical characteristics will also be allowed on this trial.
Patients with biopsy proven high grade glioma (excluding GBM) and a gross total resection and patients with non-disseminated atypical teratoid rhabdoid (ATRT) may also be included.
Pathologic diagnosis must be based on pathology or pathology review by Department of Pathology at MGH or another DF/HCC institution.
Age between 1-25 years.
Life expectancy of greater than 1 year.
ECOG Performance Status 0, 1, 2 or 3 or Lansky performance status 30 or greater.
Girls and women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
Participants who have had radiotherapy to the site to be treated.
Participants with known spinal or distant metastases. Patients with ependymoma, medulloblastoma or germinoma must have metastatic workup including spine MRI to rule out metastases.
Uncontrolled intercurrent illness that would limit compliance with study requirements.
Pregnant or breastfeeding women.
Patients who cannot participate in contributing to the neurocognitive outcomes due to severe neurologic impairment or language barrier (ie not English or Spanish speaking) will be excluded from this study.
Keywords provided by Torunn Yock, MD, Massachusetts General Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Neoplasms
Nervous System Neoplasms Neoplasms by Site Neoplasms Brain Diseases Neoplasms, Neuroepithelial
Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue
Central Nervous System Diseases
Nervous System Diseases